Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose 6-way crossover study of inhaled AZD8683 in COPD
2012-002900-42Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD8683 in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by AstraZeneca. Primary endpoint: Peak forced expiratory volume in 1 second (FEV1). Started Jul 2012; status: terminated.
02
Drugs
AZD8683
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-002900-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002900-42.